1. DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn's Disease. (21st January 2022) Authors: Wang, Z; Kantasiripitak, W; Verstockt, B; João, S; Ferrante, M; Declerck, P; D'Haens, G; Laharie, D; Vermeire, S; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases. (27th May 2021) Authors: Kantasiripitak, W; van Hoeve, K; Sabino, J; Vermeire, S; Hoffman, I; Declerck, P; Thomas, D; Ferrante, M; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S332 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach. (21st January 2022) Authors: Kantasiripitak, W; Outtier, A; Thomas, D; Kensert, A; Wang, Z; Sabino, J; Wicha, S G; Vermeire, S; Ferrante, M; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i350 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P497 The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn's disease. (27th May 2021) Authors: Kantasiripitak, W; Mathôt, R; Oldenburg, B; Buisson, A; Ferrante, M; Laharie, D; D'Haens, G; Vermeire, S; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases. (30th January 2023) Authors: Kantasiripitak, W; WIcha, S G; Thomas, D; Hoffman, I; Ferrante, M; Vermeire, S; van Hoeve, K; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i659 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases. (21st January 2022) Authors: Kantasiripitak, W; Outtier, A; Thomas, D; Sabino, J; Vermeire, S; Ferrante, M; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis. (25th January 2019) Authors: Kantasiripitak, W; Dreesen, E; Detrez, I; Stefanović, S; Drobne, D; Vermeire, S; Ferrante, M; Gils, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval. (30th January 2023) Authors: Kantasiripitak, W; Outtier, A; Thomas, D; Sabino, J; Vermeire, S; Ferrante, M; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i833 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗